Table 1
Clinical characteristics, treatment regimens, and adverse events with subconjunctival steroid injection
| Patient age, sex | Scleritis type | Associated disease | Systemic treatment before SCI | Side effects from systemic treatment | Prednisone dose followed by relapse before SCI | Duration of scleritis before SCI (months) | Systemic treatment after SCI (last follow up) | Follow up (months) | Side effects from SCI |
|---|---|---|---|---|---|---|---|---|---|
| SCI, subconjunctival injection of triamcinolone acetonide; CsA, cyclosporine; MMF, mycophenolate mofetil; Pred, prednisone; UTI, urinary tract infection; GERD, gastro-oesophageal reflux disease. | |||||||||
| Doses in the table indicate daily oral dose for Prednisone and CsA and weekly dose for methotrexate. | |||||||||
| *The patient was HLAB27 positive but did not have any associated systemic manifestations. | |||||||||
| 1, 57, F | Nodular anterior both eyes | Mixed connective tissue disease (inactive) | Pred 15 mg MTX 12.5 mg | Osteoporosis Weight gain | 7.5 mg | 63 | None | 22 | None |
| 2, 41, M | Diffuse anterior both eyes | None* | Pred 9 mg MMF 2 g | Pneumonia | 9 mg | 14 | Pred 4 mg MMF 2 g | 19 | Transient IOP increase LE |
| 3, 56, F | Diffuse anterior both eyes | Sjogren’s syndrome (inactive) | Pred 20 mg MTX 20 mg | Weight gain Myopathy Recurrent UTI GERD | 15 mg | 36 | Pred 5 mg MTX 25 mg | 17 | None |
| 4, 11, M | Diffuse anterior both eyes+ Posterior left eye | None | Pred 50 mg CsA 150 mg | Weight gain Persistent headache | 50 mg | 11 | Pred 10 mg | 5 | Subconjunctival haemorrhage, Transient IOP increase LE |
